Novartis rare-disease drug fails pivotal trial; Novo Nordisk setback noted

Novartis' experimental therapy for a rare neuromuscular condition missed its primary endpoint in a pivotal study, failing to improve muscle function. This adds to a string of recent clinical setbacks for the company. The failure raises uncertainty over the drug's regulatory path and commercial prospects, though the specific disease and trial details remain limited.